Corticosteroids for treating optic neuritis

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 8, 2015, Pages

  Gal, Robin L ^a   Vedula, Satyanarayana S ^b   Beck, Roy ^a  

^a JAEB CENTER FOR HEALTH RESEARCH   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; ANTIINFLAMMATORY AGENT; GLUCOCORTICOID; PREDNISONE;

ACNE; ACUTE PANCREATITIS; BODY WEIGHT GAIN; CONSTIPATION; CONTRAST SENSITIVITY; CONVALESCENCE; DENMARK; DEPRESSION; DIARRHEA; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; FEVER; FLUSHING; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GERMANY; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INDIA; JAPAN; META ANALYSIS; MOOD CHANGE; OPTIC NEURITIS; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SLEEP DISORDER; STOMACH DISEASE; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNITED KINGDOM; UNITED STATES; VISION; VISUAL ACUITY; VISUAL FIELD; ACUTE DISEASE; DRUG EFFECTS; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ANTI-INFLAMMATORY AGENTS; CONTRAST SENSITIVITY; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METHYLPREDNISOLONE; OPTIC NEURITIS; PREDNISONE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VISUAL ACUITY;

EID: 85016923950     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD001430.pub4     Document Type: Review

References (90)

1. Hickman SJ, Kapoor R, Jones SJ, Altmann DR, Plant GT, Miller DH. Corticosteroids do not prevent optic nerve atrophy following optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry 2003;74(8):1139-41.
2. Jones SJ, Miller DH, Kapoor R, Brusa A, Plant G. Double-blind controlled trial of methylprednisolone treatment for acute optic neuritis: 6-month follow-up with visual evoked potential measurement. Multiple Sclerosis 1996;2 Suppl:32-3.
3. Kapoor R, Miller DH, Jones SJ, Plant GT, Brusa A, Gass A, et al. Effects of intravenous methylprednisolone on outcome in MRI-based prognostic subgroups in acute optic neuritis. Neurology 1998;50(1):230-7.
4. Menon V, Mehrotra A, Saxena R, Jaffery NF. Comparative evaluation of megadose methylprednisolone with dexamethasone for treatment of primary typical optic neuritis. Indian Journal of Ophthalmology 2007;55(5):355-9.
5. Tabuchi A, Kimura H, Inoue M. Optic neuritis treatment trial: Contrast sensitivity; assessment and results. Neuro-Ophthalmology Japan 1998;15(1):30-6.
6. Wakakura M, Mashimo K, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Multicenter clinical trial for evaluating methylprednisolone pulse treatment of idiopathic optic neuritis in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Japanese Journal of Ophthalmology 1999;43(2):133-8.
7. Wakakura M, Minei Higa R, Oono S, Matsui Y, Tabuchi A, Kani K, et al. Baseline features of idiopathic optic neuritis as determined by a multicenter treatment trial in Japan. Optic Neuritis Treatment Trial Multicenter Cooperative Research Group (ONMRG). Japanese Journal of Ophthalmology 1999;43(2):127-32.
8. Beck R. The Optic Neuritis Treatment trial: three-year follow-up results. Archives of Ophthalmology 1995;113(2):136-7.
9. Beck RW, Cleary PA. Optic neuritis treatment trial. One year follow-up results. Archives of Ophthalmology 1993;111(6):773-5.
10. Beck RW, Cleary PA, Andersen MMJ, Keltner JL, Shults WT, Kaufman DI, et al. A randomized controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. New England Journal of Medicine 1992;326(9):581-8.
11. Beck RW, Cleary PA, Backlund JC. The course of visual recovery after optic neuritis. Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1994;101(11):1771-8.
12. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. New England Journal of Medicine 1993;329(24):1764-9.
13. Beck RW, Gal RL. Treatment of acute optic neuritis - A summary of findings from the Optic Neuritis Treatment Trial. Archives of Ophthalmology 2008;126(7):994-5.
14. Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the Optic Neuritis Treatment Trial. American Journal of Ophthalmology 2004;137(1):77-83.
15. Beck RW, Gal RL, et al. Optic Neuritis Treatment Trial: 10-Year Follow-up Results - Reply. American Journal of Ophthalmology 2004;138(4):695.
16. Beck RW, Kupersmith MJ, Clearly PA, Katz B, The Optic Neuritis Study Group. Fellow eye abnormalities in acute unilateral optic neuritis - Experience of the Optic Neuritis Treatment Trial. Ophthalmology 1993;100(5):691-8.
17. Beck RW, Trobe JD. The Optic Neuritis Treatment Trial - Putting the results in perspective. Journal of Neuro-Ophthalmology 1995;15(3):131-5.
18. Beck RW, Trobe JD. What we have learned from the Optic Neuritis Treatment Trial. Ophthalmology 1995;102(10):1504-8.
19. Chrousos GA, Kattah JC, Beck RW, Cleary PA. Side effects of glucocorticoid treatment. Experience of the Optic Neuritis Treatment Trial. JAMA 1993;269(16):2110-2.
20. Cleary PA, Beck RW, Anderson MMJ, Kenny DJ, Backlund JY, Gilbert PR. Design, methods, and conduct of the Optic Neuritis Treatment Trial. Controlled Clinical Trials 1993;14(2):123-42.
21. Cleary PA, Beck RW, Bourque LB, Backlund JC, Miskala PH. Visual symptoms after optic neuritis - Results from the Optic Neuritis Treatment Trial. Journal of Neuro-Ophthalmology 1997;17(1):18-28.
22. Cole SR, Beck RW, Moke PS, Gal RL, Long DT. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. The Optic Neuritis Treatment Trial. Investigative Ophthalmology and Visual Science 2000;41(5):1017-21.
23. Keltner JK, Johnson CA, Cello KE, Dontchev M, Gal RL, Beck RW, et al. Visual field profile of optic neuritis - A final follow-up report from the Optic Neuritis Treatment Trial from baseline through 15 years. Archives of Ophthalmology 2010;128(3):330-7.
24. Keltner JK, Johnson CA, Spurr JO, Beck RW, the Optic Neuritis Study Group. Baseline visual field profile of optic neuritis - The experience of the Optic Neuritis Treatment Trial. Archives of Ophthalmology 1993;111(2):231-4.
25. Keltner JL, Johnson CA, Spurr JO, Beck RW. Comparison of central and peripheral visual field properties in the Optic Neuritis Treatment Trial. American Journal of Ophthalmology 1999;128(5):543-53.
26. Keltner JL, Johnson CA, Spurr JO, Beck RW. Visual field profile of optic neuritis. One year follow-up in the Optic Neuritis Treatment Trial. Archives of Ophthalmology 1994;112(7):946-53.
27. Long DT, Beck RW, Moke PS, Blair RC, Kip KE, Gal RL, et al. The SKILL card test in optic neuritis: experience of the Optic Neuritis Treatment Trial. Journal of Neuro-Ophthalmology 2001;21(2):124-31.
28. Noseworthy J. Corticosteroids for optic neuritis and subsequent development of multiple sclerosis. Annals of Neurology 1994;120(Suppl 3):61.
29. Optic Neuritis Study Group. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis. Archives of Ophthalmology 2003;121(7):944-9.
30. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final Optic Neuritis Treatment Trial follow-up. Archives of Neurology 2008;65(6):727-32.
31. Optic Neuritis Study Group. Neurologic impairment 10 years after optic neuritis. Archives of Neurology 2004;61(9):1386-9.
32. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: Experience of the Optic Neuritis Treatment Trial. Neurology 1997;49(5):1404-13.
33. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology 2008;115(6):1079-82.
34. Optic Neuritis Study Group. Visual function 5 years after optic neuritis: Experience of the Optic Neuritis Treatment Trial. Archives of Ophthalmology 1997;115(12):1545-52.
35. Trobe JD, Arbor A, The Optic Neuritis Study Group. One-year results in the Optic Neuritis Treatment Trial. Neurology 1993;43:A280.
36. Trobe JD, Beck RW, Moke PS, Cleary PA. Contrast sensitivity and other vision tests in the Optic Neuritis Treatment Trial. American Journal of Ophthalmology 1996;121(5):547-53.
37. Frederiksen JL. A double-blind randomized study of oral prednisolone versus placebo in patients with acute optic neuritis. Canadian Journal of Neurological Sciences 1993;20(Suppl 4):Abstract no. 7-18-15.
38. Sellebjerg F, Christiansen M, Jensen J, Frederiksen J. Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis. European Journal of Neurology 2000;7(3):281-9.
39. Sellebjerg F, Jensen CV, Larsson HB, Frederiksen JL. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Multiple Sclerosis 2003;9(1):102-7.
40. Sellebjerg F, Nielsen HS, Frederiksen JL, Olesen J. A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis. Neurology 1999;52(7):1479-84.
41. Sellebjerg F, Schaldemose Nielsen H, Frederiksen JL, Olesen J. A placebo-controlled treatment trial of oral high-dose methylprednisolone in acute optic neuritis. Multiple Sclerosis 1998;4:381.
42. Katz B. The Tübingen Study on Optic Neuritis Treatment--a prospective, randomized and controlled trial. Survey of Ophthalmology 1994;39(3):262-3.
43. Trauzettel-Klosinski S. The Aulhorn flicker test: possibilities and limits. Its use in optic neuritis for diagnosis, differential diagnosis, monitoring the course of the disease, and assessing the effect of oral prednisolone. German Journal of Ophthalmology 1992;1(6):415-23.
44. Trauzettel-Klosinski S, Aulhorn E, Diener HC, Minder C, Pfluger D. The influence of prednisolone on the course of optic neuritis. Results of a double-blind study [Der einfluss von prednisolon auf den verlauf der neuritis nervi optici. Ergebnisse einer doppelblindstudie]. Fortschritte Der Ophthalmologie 1991;88(5):490-501.
45. Trauzettel-Klosinski S, Axmann D, Diener HC. The Tübingen Study on Optic Neuritis Treatment - A prospective, randomized and controlled trial. Clinical Vision Sciences 1993;8(4):385-94.
46. Trauzettel-Klosinski S, Diener HC, Dietz K, Zrenner E. The effect of oral prednisolone on visual evoked potential latencies in acute optic neuritis monitored in a prospective, randomized, controlled study. Documenta Ophthalmologica 1996;91(2):165-79.
47. Al-Eajailat SM, Al-Madani Senior MV. The role of magnetic resonance imaging and visual evoked potential in management of optic neuritis. Pan African Medical Journal 2014;17:54.
48. Alejandro PM, Castanon Gonzalez JA, Miranda Ruiz R, Edgar Echeverria R, Adriana Montano M. Comparative treatment of acute optic neuritis with "boluses" of intravenous methylprednisolone or oral prednisone [Tratamiento comparativo de la neuritis optica aguda con "bolos" de metilprednisolona endovenosa o prednisona oral]. Gaceta Medica de Mexico 1994;130(4):227-30.
49. Beran V, Hradecka V, Kohoutova O. Comparison of stimulation therapy with glucocorticoid therapy in optic nerve inflammation [Porovnani popudove terapie s lecbou glukokortikoidy u zanetu zrakoveho nervu]. Ceskoslovenska Oftalmologie 1973;29(5):372-4.
50. Bhatti MT, Schmitt NJ, Beatty RL. Acute inflammatory demyelinating optic neuritis: current concepts in diagnosis and management. Optometry 2005;76(9):526-35.
51. Bird AC. Treatment of acute optic neuritis. Transactions of the Ophthalmological Societies of the United Kingdom 1976;96(3):412-4.
52. Bowden AN, Bowden PMA, Friedman AI, Perkin GD, Rose FC. A trial of corticotrophin gelatin injection in acute optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry 1974;37(8):869-73.
53. Brusa A, Jones SJ, Kapoor R, Miller DH, Plant GT. Long-term recovery and fellow eye deterioration after optic neuritis, determined by serial visual evoked potentials. Journal of Neurology 1999;246(9):776-82.
54. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. Journal of Neurology 2000;247(6):435-42.
55. Chuman H. 41st Annual Meeting of the Japanese Neuro-Ophthalmology Society, Kyoto, Japan, December 12-13, 2003. Journal of Neuro-Ophthalmology 2004;24(2):170-4.
56. Gould ES, Bird AC, Leaver PK, McDonald WI. Treatment of optic neuritis by retrobulbar injection of triamcinolone. British Medical Journal 1977;1(6075):1495-7.
57. Hallermann W, Haller P, Krüger C, Schiemann M, Patzold U. Progress of optic neuritis with and without corticosteroid treatment. Findings in a long-term investigation with static perimetry. Fortschritte der Ophthalmologie 1983;80(1):30-4.
58. Hickman S. NOON. Nitric oxide in optic neuritis: A phase I randomised double-blind study of rapid corticosteroid treatment of optic neuritis. National Research Register, UK 2002.
59. Kommerell G. Treatment of optic neuritis with corticosteroids. Discussion at the 10th Meeting of the International Neuro-ophthalmological Society (Freiburg 5 to 9 June 1994) [Die Behandlung der Neuritis nervi optici mit Kortikosteroiden. Diskussion bei der 10. Tagung der International Neuro-ophthalmological Society (Freiburg, 5. bis 9. Juni 1994)]. Klinische Monatsblatter Fur Augenheilkunde 1994;205(3):126-7.
60. Kott E, Kessler A, Biran S. Optic neuritis in multiple sclerosis patients treated with copaxone. Journal of Neurology 1997;244:S23-4.
61. Midgard R, Seland JH, Hovdal H, Celius EG, Eriksen K, Jensen D, et al. Optic neuritis: diagnosis, treatment and follow-up. Tidsskrift for Den Norske Laegeforening 2005;125(4):425-8.
62. Midgard R, Seland JH, Hovdal H, Celius EG, Eriksen K, Jensen D, et al. Retraction of article [Tilbaketrekking av artikkel.]. Tidsskrift for den Norske Laegeforening 2005; Vol. 125, issue 15:2056.
63. Park JH, Shin JP, Chun BY. Additional retrobulbar triamcinolone acetonide injection for retrobulbar optic neuritis patients. Journal of the Korean Ophthalmological Society 2013;54(1):117-22.
64. Pirko I, Blauwet LK, Lesnick TG, Weinshenker BG. The natural history of recurrent optic neuritis. Archives of Neurology 2004;61(9):1401-5.
65. Rawson M, Liversedge LA, Goldfarb G. Treatment of acute retrobulbar neuritis with corticotrophin. Lancet 1966;2(7472):1044-6.
66. Rawson MD, Liversedge LA. Treatment of retrobulbar neuritis with corticotrophin. Lancet 1969;294(7613):222.
67. Roed HG, Langkilde A, Sellebjerg F, Lauritzen M, Bang P, Morup A, et al. A double-blind randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 2005;64(5):804-10.
68. Soderstrom M. Corticosteroids and acute optic nerve neuritis. A therapeutic method requiring further studies. [Kortikosteroider och akut opticusneurit. Behandlingsmetod kräver ytterligare studier]. Lakartidningen 1995;92(5):387-90.
69. Toczolowski J, Lewandowska-Furmanik M, Stelmasiak Z, Wozniak D, Chmiel M. Treatment of acute optic neuritis with large doses of corticosteroids [Leczenie ostrego zapalenia nerwu wzrokowego za pomoca duzych dawek kortykosterydow]. Klinika Oczna 1995;97(5):122-5.
70. NCT01524250. Optic neuritis recovery after oral or IV corticosteroids. clinicaltrials.gov/ct2/show/NCT01524250 (accessed 11 June 2015).
71. NCT01838174. A phase IV trial of neuroprotection with ACTH in acute optic neuritis (ACTHAR). clinicaltrials.gov/ct2/show/NCT01838174 (accessed 11 June 2015).
72. Beck RW. Optic Neuritis. In: Miller NR, Newman NJ editor(s). Walsh and Hoyt's Neuro-ophthalmology. 5th Edition. Baltimore: Williams and Wilkins, 1998:599-647.
73. Bennett JL, Nickerson M, Costello F, Sergott RC, Calkwood JC, Galetta SL, et al. Re-evaluating the treatment of acute optic neuritis. Journal of Neurology, Neurosurgery and Psychiatry 2015;86(7):799-808.
74. de la Cruz J, Kupersmith MJ. Clinical profile of simultaneous bilateral optic neuritis in adults. British Journal of Ophthalmology 2006;90(5):551-4.
75. Ebers GC. Optic neuritis and multiple sclerosis. Archives of Neurology 1985;42(7):702-4.
76. Fleishman JA, Beck RW, Linares OA, Klein JW. Deficits in visual function after resolution of optic neuritis. Ophthalmology 1987;94(8):1029-35.
77. Glanville JM, Lefebvre C, Miles JN, Camosso-Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130-6.
78. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
79. Koch-Henriksen N, Hyllested K. Epidemiology of multiple sclerosis: incidence and prevalence rates in Denmark 1948-64 based on the Danish Multiple Sclerosis Registry. Acta Neurologica Scandinavica 1988;78(5):369-80.
80. Kurtzke JF. Optic neuritis or multiple sclerosis. Archives of Neurology 1985;42(7):704-10.
81. Lightman S, McDonald WI, Bird AC, Francis DA, Hoskins A, Batchelor JR, et al. Retinal venous sheathing in optic neuritis. Its significance for the pathogenesis of multiple sclerosis. Brain 1987;110(Pt 2):405-14.
82. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD, et al. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ. Archives of Ophthalmology 1998;116(11):1496-504.
83. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
84. Rodriguez M, Siva A, Cross SA, O'Brien PC, Kurland LT. Optic neuritis: a population-based study in Olmsted County, Minnesota. Neurology 1995;45(2):244-50.
85. Sanders EA, Volkers AC, van der Poel JC, van Lith GH. Estimation of visual function after optic neuritis: a comparison of clinical tests. British Journal of Ophthalmology 1986;70(12):918-24.
86. Spoor TC, Rockwell DL. Treatment of optic neuritis with intravenous megadose corticosteroids. A consecutive series. Ophthalmology 1988;95(1):131-4.
87. Toosy AT, Mason DF, Miller DH. Optic neuritis. Lancet Neurology 2104;13(1):83-99.
88. Gal R, Brodney-Folse S, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database of Systematic Reviews 2002, Issue 3. [DOI: 10.1002/14651858.CD001430]
89. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD001430.pub3]
90. Vedula SS, Brodney Folse S, Gal RL, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD001430.pub2]